HPGC Renmintongtai Pharmaceutical Corporation reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 2,328.67 million compared to CNY 2,162.13 million a year ago. Revenue was CNY 2,328.67 million compared to CNY 2,162.13 million a year ago. Net income was CNY 46.13 million compared to CNY 40.02 million a year ago. Basic earnings per share from continuing operations was CNY 0.0795 compared to CNY 0.069 a year ago. Diluted earnings per share from continuing operations was CNY 0.0795 compared to CNY 0.069 a year ago.